
\begin{tabular}[t]{llll}
\toprule
\multicolumn{1}{c}{ } & \multicolumn{2}{c}{CDK4/6i} & \multicolumn{1}{c}{HT} \\
\cmidrule(l{3pt}r{3pt}){2-3} \cmidrule(l{3pt}r{3pt}){4-4}
Â  & Palbociclib & Ribociclib & \\
\midrule
 & (N=247) & (N=106) & (N=43)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Age at treatment start}}\\
\hspace{1em}Mean (SD) & 59.2 (11.7) & 58.2 (10.7) & 60.1 (12.4)\\
\hspace{1em}Median [Min, Max] & 60.0 [28.0, 84.0] & 58.0 [32.0, 79.0] & 62.0 [34.0, 85.0]\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Estrogen Receptor}}\\
\hspace{1em}+ & 247 (100 \%) & 106 (100 \%) & 42 (98 \%)\\
\hspace{1em}- & NA & NA & 1 (2 \%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Progesterone Receptor}}\\
\hspace{1em}+ & 192 (78 \%) & 80 (75 \%) & 27 (63 \%)\\
\hspace{1em}- & 55 (22 \%) & 26 (25 \%) & 16 (37 \%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Bone Only metastases}}\\
\hspace{1em}No & 161 (65 \%) & 74 (70 \%) & NA\\
\hspace{1em}Yes & 86 (35 \%) & 32 (30 \%) & NA\\
\hspace{1em}Missing & 0 (0\%) & 0 (0\%) & 43 \vphantom{1} (100\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Visceral metastasis}}\\
\hspace{1em}No & 122 (49 \%) & 49 (46 \%) & NA\\
\hspace{1em}Yes & 125 (51 \%) & 57 (54 \%) & NA\\
\hspace{1em}Missing & 0 (0\%) & 0 (0\%) & 43 (100\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Stage}}\\
\hspace{1em}I & 22 (9 \%) & 7 (7 \%) & 3 (7 \%)\\
\hspace{1em}II & 75 (30 \%) & 22 (21 \%) & 20 (47 \%)\\
\hspace{1em}III & 75 (30 \%) & 18 (17 \%) & 11 (26 \%)\\
\hspace{1em}IV & 65 (26 \%) & 46 (43 \%) & 2 (5 \%)\\
\hspace{1em}Missing & 10 (4.0\%) & 13 (12.3\%) & 7 (16.3\%)\\
\addlinespace[0.3em]
\multicolumn{4}{l}{\textbf{Drug/Combination}}\\
\hspace{1em}Anastrozol & NA & NA & 3 (7 \%)\\
\hspace{1em}Exemestane & 1 (0 \%) & NA & 4 (9 \%)\\
\hspace{1em}Fulvestrant & 180 (73 \%) & 10 (9 \%) & 5 (12 \%)\\
\hspace{1em}Letrozol & 66 (27 \%) & 96 (91 \%) & 31 (72 \%)\\
\bottomrule
\end{tabular}
